IN THE CLAIMS:

Claims 37-39, 41, 42, and 45-47 have been amended herein. Claims 35, 40, 44, 48-55, and 57 have been canceled without prejudice or disclaimer. Please note that all claims currently pending and under consideration in the above-referenced application are shown below. Please enter these claims as amended. This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-36. (Canceled)

37. (Currently Amended) The oral sustained-release pharmaceutical composition according to ~~claim 35~~claim 45, wherein the oral sustained-release pharmaceutical composition releases the active compound at a rate sufficient to maintain a therapeutically effective serum concentration of the active compound for at least 8 hours.

38. (Currently Amended) The oral sustained-release pharmaceutical composition according to ~~claim 35~~claim 45, wherein the oral sustained-release pharmaceutical composition releases the active compound at a rate sufficient to maintain a therapeutically effective serum concentration of the active compound for at least 12 hours.

39. (Currently Amended) The oral sustained-release pharmaceutical composition according to ~~claim 35~~claim 45, wherein the gelling agent comprises xanthan gum.

Claim 40. (Canceled)

41. (Currently Amended) The oral sustained-release pharmaceutical composition according to ~~claim 35~~claim 45, further comprising at least one excipient.

42. (Currently Amended) The oral sustained-release pharmaceutical composition according to ~~claim 35~~claim 45, wherein the active compound is isovaleramide.

Claims 43-44. (Canceled)

45. (Currently Amended) ~~The oral sustained-release pharmaceutical composition according to claim 44, wherein the~~ An oral sustained-release pharmaceutical composition comprising a core matrix comprising a therapeutically effective amount of an active compound, a gelling agent, and a polymeric coating material ~~comprises~~ comprising a mixture of ethyl cellulose and hydroxypropyl methylcellulose that retards access of liquids to the active compound and/or retards release of the active compound through the film-coating, wherein the amount of the active compound represents from about 40% to about 70% by weight of the oral-sustained release pharmaceutical composition, and wherein the active compound is selected from the group consisting of: isovaleric acid, a pharmaceutically acceptable salt of isovaleric acid, a pharmaceutically acceptable ester of isovaleric acid, a compound having the structure:



wherein A = H, CH_3, or OH,

B = H, OH, or CH_3,

X = CH_2, $CHCH_3$, $C(CH_3)_2$, -O-, CH(OH), or $-CH_2O-$,

Y = -CO-, or $-SO_2-$, and

Z = H, CH_2CO_2H, or CH_2CONH_2,

and a compound selected from the group consisting of isovaleramide, 2-methylisovaleramide, 3-methylisovaleramide, 2,2-dimethylisovaleramide, 2,3-dimethylisovaleramide, 4-methylisovaleramide, 2,4-dimethylisovaleramide, 3,4-dimethylisovaleramide, 2,2,4-trimethylisovaleramide, 3-hydroxyisovaleramide, 4-

hydroxyisovaleramide, 4-hydroxy-3-methyl-isovaleramide, 2-hydroxyisovaleramide, N-(2-acetamido)isovaleramide, 2-methyl-1-propylsulfonamide, 1-methylethyl sulfamate, 2-methyl-1-propyl sulfamate, isopropyl carbamate, and isobutylcarbamate.

46. (Currently Amended) The oral sustained-release pharmaceutical composition according to ~~claim 44~~claim 45, wherein the polymeric coating material further comprises a plasticizer.

47. (Currently Amended) The oral sustained-release pharmaceutical composition according to ~~claim 35~~claim 45, wherein the oral sustained-release pharmaceutical composition is in the form of a tablet, capsule, or multiparticulate composition.

Claims 48-59. (Canceled)